Replies to post #137561 on Biotech Values

[ghmm]

Does anyone know if Roche ever published (or even released) SVR data from the first INFORM study? Granted it was small and treatment duration was limited (with the DUAL Oral agents) before patients went on PEG/Riba but I would be curious to know how the patients faired.

[DewDiligence]

Only six people have voted in the #msg-72378069 survey so far. This, too, is surprising given the level of interest in HCV on this board.

[DewDiligence]

Voting in HCV survey in #msg-72378069 (9 votes cast):

Q: In treatment-naive genotype-1a patients, what is the worst-case
SVR rate you expect in the first credible trial testing two direct-acting
antiviral agents without interferon or ribavirin?

a) >90%: 0%
b) 80-90%: 22%
c) 65-80%: 22%
d) 50-65%: 44%
e) <50%: 11%

The distribution of responses seems reasonable (I voted for d) ), but I’m surprised that there was not more interest in this survey.